Support for a tax increase to provide unrestricted access to an Alzheimer's disease medication: a survey of the general public in Canada

Table 3 Exploratory analyses: summary of regression models

Variable	S1		S2		S3		S4
	FM	RM	FM	RM	FM	RM	FM	RM
Alzheimer's disease knowledge score							√	√
Age				√			√	√
Sex
EQ-5D Index (current health state)
EQ-5D Index (participants assume they have Alzheimer's disease)	√	√
Annual household income*							√	√
Region of residence
Highest level of education completed
Employment status
Participant knows a family member or close friend with Alzheimer's disease
Family members' or friends' level of approval of a participant's decision to support a tax increase^†	√	√	√	√	√	√	√	√

S1 = scenario 1 (symptom treatment, no adverse effects); S2 = scenario 2 (symptom treatment, 30% chance of adverse effects); S3 = scenario 3 (disease modification, no adverse effects); S4 = scenario 4 (disease modification, 30% chance of adverse effects); FM = full model; RM = reduced model; √ = variable is significant at the 5% level (p < 0.05) in the model.
*Only the '$60,000 to less than $80,000' category (versus 'less than $20,000') is significant at the 5% level.
^†Only the 'somewhat approve' and 'strongly approve' categories (versus 'strongly disapprove') are significant at the 5% level.

ISSN: 1472-6963